Clinical trials: Lymphoma, Hodgkins
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma
Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma
This phase I trial tests the safety, side effects and best dose of azacitidine in combination with belinostat and how well the combination works in treating patients with follicular helper T cell lymphoma (TFH) that has come back…
- Conditions
- Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
- Trial name
- NCT07691450
- Testing
- Azacitidine, Belinostat, Biospecimen Collection
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- City of Hope Medical Center
Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
This phase II study is designed to determine the clinical efficacy of PD-1 blockade, using the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475), administered as consolidation therapy after autologous stem cell transplant…
- Conditions
- Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
- Trial name
- NCT02362997
- Testing
- Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 82 people
- Sponsor
- Dana-Farber Cancer Institute
Neoplasms, Non-Hodgkin Lymphoma
Study of TPI 287 in Patients With Advanced Malignancies
Tapestry Pharmaceuticals, Inc. has developed a novel taxane analog, TPI 287. TPI 287 is synthetically manufactured from naturally occurring taxanes extracted from yew starting material.
- Conditions
- Neoplasms, Non-Hodgkin Lymphoma, Hodgkin Disease
- Trial name
- NCT00113724
- Testing
- TPI 287 Injection
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Cortice Biosciences, Inc.
NHL
A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
This is a Phase I Clinical Study to Evaluate the Safety, Efficacy, and PK/PD Characteristics of HSK47977 Tablets in Subjects with Relapsed or Refractory Non-Hodgkin's Lymphoma.This study includes a Phase Ia dose-escalation stage…
- Trial name
- NCT07283796
- Testing
- HSK47977
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Non-Hodgkin's Lymphoma, Lymphoma, B-Cell
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG
The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma (NHL) at different dose levels.
- Trial name
- NCT00061425
- Testing
- radiolabeled epratuzumab
- Sponsor
- Gilead Sciences
Primary Central Nervous System Lymphoma
Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System
Primary central nervous system lymphomas are rare aggressive malignancies, usually treated in two steps: an induction phase (where a combination of chemotherapy is given) followed by a consolidation phase (where patients usually…
- Trial name
- FIORELLA (NCT03495960)
- Testing
- Rituximab, Methotrexate, Procarbazine
- Where
- 34 sites in Denmark, Finland and 2 more
- Volunteers
- 72 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Acute Myeloid Leukemia, Hematologic Malignancies
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
This phase I trial studies the side effects and best dose of targeted marrow irradiation when given with fludarabine phosphate and busulfan before donor progenitor cell transplant in treating patients with hematologic…
- Conditions
- Acute Myeloid Leukemia, Hematologic Malignancies, Acute Lymphocytic Leukemia, Non Hodgkin Lymphoma
- Trial name
- NCT02129582
- Testing
- total marrow irradiation, fludarabine phosphate, busulfan
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
Relapsed or Refractory Hodgkin Lymphoma, Children
Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment
Children with relapsed or refractory Hodgkin lymphoma receive 3-6 cycles of nivolumab monotherapy. In case of achieving complete response (CR) auto-HSCT is performed.
- Conditions
- Relapsed or Refractory Hodgkin Lymphoma, Children, Nivolumab, Autologous Haemopoietic Stem Cell Transplant
- Trial name
- NCT06931613
- Testing
- Nivolumab
- Where
- 2 sites in Russia
- Volunteers
- 20 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Lymphoma
Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002488
- Testing
- cisplatin, cyclophosphamide, etoposide
- Where
- 2 sites in Canada
- Sponsor
- Ottawa Regional Cancer Centre
Hodgkin Lymphoma
Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen
The DP regimen, low-dose decitabine combined with SHR-1210, is the new treatment for relapsed or refractory classical Hodgkin's Lymphoma.
- Trial name
- NCT04026269
- Testing
- MOAP
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Han weidong
Leukemia, Lymphoma
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Tretinoin may help hematologic cancer cells develop into normal white blood cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006220
- Testing
- arsenic trioxide, tretinoin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia, Lymphoblastic Leukemia
Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
This is a phase I study using Intensity Modulated Total Marrow Irradiation (IM-TMI) in addition to a chemotherapy regimen in preparation for an allogeneic stem cell transplant for advanced hematologic malignancies such as acute…
- Conditions
- Acute Myeloid Leukemia, Lymphoblastic Leukemia, Acute Leukemia, Non Hodgkins Lymphoma
- Trial name
- IM-TMI (NCT00988013)
- Testing
- IM-TMI (3Gy), IM-TMI (6Gy), IM-TMI (9Gy)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Illinois Chicago
Lymphoma, Hodgkin's Lymphoma
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
To determine the recommended phase 2 dose of chemotherapy in combination with Pembrolizumab in subjects with advanced lymphoma and determine the complete response rate.
- Conditions
- Lymphoma, Hodgkin's Lymphoma, Non-hodgkin's Lymphoma
- Trial name
- NCT02408042
- Testing
- Pembrolizumab, Etoposide, Ifosfamide
- Where
- United States
- Sponsor
- Western Regional Medical Center
Tumors, Non-Hodgkins's Lymphoma
Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.
This is an open-label, randomized, multiple-dose, multicenter Pharmacokinetics drug-drug interaction study in patients with advanced solid tumors, including non-Hodgkin's lymphoma, who are in need of anti-tumor therapy.
- Trial name
- NCT00298779
- Testing
- omeprazole and bortezomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Cancer
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety in patients with cancer.
- Trial name
- NCT01611623
- Testing
- SNX-5422
- Volunteers
- 9 people
- Sponsor
- Esanex Inc.
Lymphoma
SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma
RATIONALE: Drugs used in chemotherapy, such as SL-11047, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00293488
- Testing
- polyamine analogue PG11047
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Progen Pharmaceuticals
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
This study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as natural killer cells that remove cancer cells.
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Multiple Myeloma
- Trial name
- NCT01643603
- Testing
- Dasatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Hodgkin Lymphoma
Genetic Study of Families With High Frequency of Hodgkin Lymphoma
Hodgkin lymphoma (HL) is a relatively rare disorder with known familiar aggregation (i.e. HL in more than one child, or parent and child).
- Trial name
- NCT02795013
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- St. Jude Children's Research Hospital
Non-Hodgkin's Lymphoma
Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and reduced delayed cardiotoxicity in animal models compared to reference standards.
- Trial name
- NCT00577161
- Testing
- fludarabine and rituximab, fludarabine, rituximab, pixantrone
- Where
- 8 sites in United States
- Sponsor
- CTI BioPharma
Hodgkin Disease, Lymphoma, Non-Hodgkin
A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation
Phase 2 study, conducted in patients with Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma undergoing high-dose chemotherapy and autologous stem cell transplantation.
- Conditions
- Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mantle Cell Lymphoma
- Trial name
- NCT00275262
- Testing
- Leuprolide acetate depot (LAD) 11.25 mg 3 Month
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Abbott
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.